耐甲氧西林金黄色葡萄球菌药物市场 - 按药物类别（糖肽）、MRSA 类型（医院获得性、社区获得性）、给药途径、适应症（菌血症）、配销通路- 全球预测（2024 - 2032）

由于抗生素诱导的金黄色葡萄球菌菌株引发的持续挑战，2024 年至 2032 年间，全球耐甲氧西林金黄色葡萄球菌药物市场规模将达到 4.2% 的复合年增长率。传统抗生素对抗甲氧西林金黄色葡萄球菌 MRSA 无效，迫切需要新的治疗方案。

製药公司、研究机构和政府机构也在加紧努力开发新药、疫苗和治疗策略来对抗 MRSA 感染。例如，2023 年 12 月，科学家利用更透明的深度学习模式发现了一类针对抗药性金黄色葡萄球菌的新型抗生素。基因组学、免疫学和药物发现机制的进步也为 MRSA 感染的发病机制和潜在的治疗标靶提供了新的见解，强调了急诊医学的重要性。对 RampD 的日益关注将推动创新并塑造 MRSA 治疗的未来。

整个产业分为药品类别、MRSA类型、给药途径、适应症、配销通路和地区。

根据药物类别，脂肽领域的抗甲氧西林金黄色葡萄球菌药物产业将在2024年至2032年经历严格的发展。活性而闻名。由于 MRSA 菌株对传统抗生素的反应较差，脂肽因其独特的作用机制和低抗药性而提供了有价值的替代品。一些製药公司也专注于开发和销售以脂肽为基础的药物，以应对日益增长的 MRSA 感染威胁。

根据MRSA类型，来自社区获得的CA-MRSA细分市场的耐甲氧西林金黄色葡萄球菌药物市场将在2024年至2032年出现显着的复合年增长率。 ，对公共卫生造成严重影响忧虑。 CA-MRSA 菌株能够在健康个体中引起严重感染，导致对有效治疗的需求不断增加。製药公司也正在关注针对 CA-MRSA 菌株的药物，以应对这一日益严重的威胁。

由于对有效治疗的需求不断增加，2024年至2032年欧洲耐甲氧西林金黄色葡萄球菌药物市场将呈现出值得称讚的复合年增长率。随着医疗保健相关和社区获得性 MRSA 感染发生率的不断增加，该地区迫切需要新的抗生素。製药公司也正在投资 RampD 活动来满足这项需求，同时推出新药来对抗欧洲 MRSA 菌株的流行。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • MRSA 感染发生率增加
    • 抗生素抗药性不断增强
    • 药物开发的进展
  • 产业陷阱与挑战
    • 治疗费用高
• 成长潜力分析
• 管道分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 醣肽类
• 脂肽
• 噁唑烷酮类
• 头孢菌素
• 四环素
• 叶酸拮抗剂
• 其他药物类别

第 6 章：市场估计与预测：按 MRSA 类型，2021 - 2032 年

• 主要趋势
• 医院获得性 (HA-MRSA)
• 社区型 (CA-MRSA)

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 口服
• 注射用

第 8 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 皮肤和软组织感染
• 骨骼和关节感染
• 呼吸道感染
• 菌血症
• 其他适应症

第 9 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 10 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• AbbVie Inc.
• Basilea Pharmaceutica Ltd
• Baxter International Inc.
• Cumberland Pharmaceuticals Inc.
• GlaxoSmithKline plc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

Global Methicillin-resistant Staphylococcus Aureus Drugs Market size will witness 4.2% CAGR between 2024 and 2032 owing to ongoing challenges, triggered by antibiotic-induced Staphylococcus aureus strains. Conventional antibiotics against methicillin-resistant staphylococcus aureus MRSA are ineffective, and new treatment options are critically needed.

Pharmaceutical companies, research institutes, and government agencies are also intensifying their efforts to develop new drugs, vaccines, and therapeutic strategies to combat MRSA infections. For instance, in December 2023, scientists discovered a new class of antibiotics for drug-resistant Staphylococcus aureus bacteria from the utilization of more transparent deep learning models. Advances in genomics, immunology, and drug discovery mechanisms are also providing new insights into the pathogenesis of MRSA infections and potential therapeutic targets for emphasizing the importance of emergency medicine. This increased focus on R&D is poised to drive innovations and shape the future of MRSA treatments.

The overall industry is classified into drug class, MRSA type, route of administration, indication, distribution channel and region.

According to drug class, the methicillin-resistant staphylococcus aureus drugs industry from the lipopeptides segment will undergo rigorous development from 2024 to 2032. Lipopeptides are promising antimicrobial agents, known for their potent activity against MRSA and other drug-resistant bacteria. As MRSA strains are poorly responsive to conventional antibiotics, lipopeptides offer valuable alternatives due to their unique mechanism of action and low resistance. Several pharmaceutical companies are also focusing on developing and marketing lipopeptide-based drugs to combat the growing threat of MRSA infections.

On the basis of MRSA type, the methicillin-resistant staphylococcus aureus drugs market from the community acquired CA-MRSA segment will register notable CAGR from 2024 to 2032. This is due to the rise in CA-MRSA infections, which pose a serious public health concern. The ability of CA-MRSA strains to cause serious infections in otherwise healthy individuals, has led to the increasing demand for effective treatment. Pharmaceutical companies are also focusing on drugs targeting CA-MRSA strains to combat this growing threat.

Europe methicillin-resistant staphylococcus aureus drugs market will showcase a commendable CAGR from 2024 to 2032 due to the increasing need for effective treatments. With the increasing incidence of healthcare-associated and community-acquired MRSA infections, new antibiotics are urgently required in the region. Pharmaceutical companies are also investing in R&D activities to meet this demand while introducing new drugs to combat the prevalence of MRSA strains in Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of MRSA infections
    • 3.2.1.2 Growing antibiotic resistance
    • 3.2.1.3 Advancements in drug development
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of therapeutics
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Glycopeptides
• 5.3 Lipopeptides
• 5.4 Oxazolidinones
• 5.5 Cephalosporin
• 5.6 Tetracycline
• 5.7 Folate antagonist
• 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By MRSA Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hospital-acquired (HA-MRSA)
• 6.3 Community-acquired (CA-MRSA)

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Skin and soft tissue infections
• 8.3 Bone & joint infections
• 8.4 Respiratory infections
• 8.5 Bacteremia
• 8.6 Other indications

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Basilea Pharmaceutica Ltd
• 11.3 Baxter International Inc.
• 11.4 Cumberland Pharmaceuticals Inc.
• 11.5 GlaxoSmithKline plc.
• 11.6 Johnson & Johnson
• 11.7 Merck & Co., Inc.
• 11.8 Novartis AG
• 11.9 Pfizer Inc.
• 11.10 Teva Pharmaceutical Industries Ltd.